Formulation and Evaluation of Eudragit L- 100 based Nanoparticles of Senna for Treatment of Constipation

Background: The pharmaceutical industries are keen in development of new herbal bioactive molecules with an improved effect and less toxicity in order to replace synthetic drugs. Constipation is the most prevalent medical concerns. It’s estimated that one in five adults worldwide suffers from constipation. Hence, the demand of herbal laxatives is increasing worldwide. The purpose of this research work was to develop Senna nanoparticles with the help of Eudragit L100 an enteric coating polymer to provide site specific activity and to prevent degradation of Senna in acidic environment. Materials and Methods: Senna loaded nanoparticles were prepared by using emulsion solvent evaporation method. Different formulation has been formulated with varying concentration of Eudragit L-100 and constant aqueous and organic phase ratio (1:9). Drug and polymer compatibility study was analysed by FTIR. The prepared formulation was characterized by melting point, particle size, zeta potential, polydispersity index, vesical morphology and in-vitro drug release. Results: All the formulation batches shows particle size between 380.61 - 1061.71nm. The zeta of optimized batch (F5) was found to be -23.75mV. Entrapment efficiency of the entire prepared formulation batch in between 3.16±0.31- 55.18±0.35%. The in-vitro drug release shows maximum drug release i.e. 61.03% in 8 hrs which shows that release of drug prolonged and site specific due to use of enteric coated polymer Eudragit L100. Conclusion: The developed Senna loaded nanoparticles can provide site specific drug delivery. The polymer used in Senna Nanoparticles formulations shows efficient and targeted drug release as well as reduction in dose, dosing frequency and side effects.